| __timestamp | Axsome Therapeutics, Inc. | Dr. Reddy's Laboratories Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 38783000000 |
| Thursday, January 1, 2015 | 2419289 | 42585000000 |
| Friday, January 1, 2016 | 6343648 | 45702000000 |
| Sunday, January 1, 2017 | 7206691 | 46372000000 |
| Monday, January 1, 2018 | 9351522 | 46910000000 |
| Tuesday, January 1, 2019 | 13598030 | 48890000000 |
| Wednesday, January 1, 2020 | 28896749 | 50129000000 |
| Friday, January 1, 2021 | 66646205 | 54559000000 |
| Saturday, January 1, 2022 | 159253661 | 62081000000 |
| Sunday, January 1, 2023 | 323123000 | 105931000000 |
| Monday, January 1, 2024 | 411359000 | 77201000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Dr. Reddy's Laboratories Limited and Axsome Therapeutics, Inc. over the past decade. From 2014 to 2023, Dr. Reddy's consistently reported higher SG&A expenses, peaking at over 105 billion in 2023, reflecting its expansive global operations. In contrast, Axsome Therapeutics, a relatively newer player, showed a dramatic increase in SG&A expenses, surging from a modest 1.4 million in 2014 to 323 million in 2023, indicating aggressive market expansion and investment in R&D. Notably, 2024 data for Axsome is missing, suggesting a potential gap in reporting. This financial trajectory highlights the contrasting growth strategies of these pharmaceutical giants, offering insights into their operational priorities and market positioning.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Biogen Inc. vs Dr. Reddy's Laboratories Limited Trends and Insights
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Jazz Pharmaceuticals plc
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Dr. Reddy's Laboratories Limited and Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Axsome Therapeutics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?